Given the resistance of Chondrosarcoma to conventional chemotherapy and radiotherapy, targeting the miR-143/145-FSCN1 axis represents a promising approach to attenuate tumor progression and improve patient outcomes. The gene discussed is FSCN1; the disease is neoplasm.